Q-omics provides the consensus-scored UBE2B profile across patient tissues and cancer cell-line models. UBE2B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, UBE2B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, UBE2B protein abundance shows 30,438 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight SCLC, KIRC, and UCEC as cancer lineages where UBE2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2B survival associations across molecular data types. UBE2B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2B RNA expression–survival associations across cancer types. High UBE2B expression shows unfavorable associations in SCLC, STAD, ESCA and KIRP, but favorable associations in KIRC and MESO. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for UBE2B RNA expression.
This table summarizes UBE2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UBE2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2B shows lower tumor expression in LUAD, LUSC, UCEC and BLCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher UBE2B RNA expression in tumor versus normal tissue (log2 FC = +0.690, t-test p < 0.001).
This table shows molecular features associated with UBE2B in patient tissues and cancer cell lines. In patient samples, UBE2B shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BONE.
